This page shows the latest Therapeutic vaccines news and features for those working in and with pharma, biotech and healthcare.
Temi Folaranmi, vice president and vaccines therapeutic area head of US Medical Affairs at GSK said: “Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunisation. ... Outlined in a US Centers for
This agreement expands our LNP capabilities and allows us to explore more projects within our existing vaccines area and new therapeutic areas where mRNA-LNP technology holds potential for success.”. ... is excited to be working with Pfizer to advance
Penny Heaton, Global Therapeutic Area Head, Vaccines, Janssen Research &Development.
Several such trials are ongoing, including the RECOVERY trial in the UK and the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) in the US.
CureVac’s candidate, like other investigational vaccines from Pfizer and BioNTech and Moderna, uses mRNA technology, which is a relatively new research area. ... The hope is that by using mRNA technology to develop vaccines and therapeutic treatments,
mRNA technology has been in the spotlight during the race to develop a COVID-19 vaccine, with a number of companies utilising this research area to develop innovative vaccines for the ... The hope is that by using mRNA technology to develop vaccines and
More from news
Approximately 0 fully matching, plus 31 partially matching documents found.
A partial revision to the Swiss Patents Act and its implementing provisions came into force on 1 January 2019, together with an ordinary revision of the Therapeutic Products Act. ... For example, over the last five years, Lundbeck acquired Prexton
You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and
Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease. ... 3 year research collaboration and exclusive licence. 509. Neuropore Therapies/UCB. To develop
Baxter forecasts that its revenues from vaccines will be approximately $300m for 2014. ... CureVac is also eligible to receive clinical, regulatory and commercial milestones of up to $202m, as well as royalty payments associated with products sales of
More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.
At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.
Together, they bring a wealth of experience to advance therapeutic vaccines for Bionor, and specifically will add operational strength to get our HIV functional cure approach advanced to patients and the
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...